Table 1.
Baseline demographic, clinical, and laboratory characteristics of the patients in this study
| Characteristic | Overall | NA naïve | LAM-F | P value |
|---|---|---|---|---|
| No. (%) of patients | 197 (100) | 105 (53) | 92 (47) | |
| Mean age (yr) ± SD | 43 ± 12 | 40 ± 12 | 45 ± 12 | 0.014 |
| No. (%) of: | ||||
| Males | 136 (69) | 73 (70) | 63 (68) | 0.87 |
| Females | 61 (31) | 32 (30) | 29 (32) | |
| No. (%) with cirrhosis | 45 (23) | 15 (14) | 30 (33) | 0.002 |
| Child-Pugh class A | 32 (71) | 13 (87) | 19 (63) | >0.05a |
| Child-Pugh class B | 11 (24) | 2 (13) | 9 (30) | >0.05a |
| Child-Pugh class C | 2 (4) | 0 (0) | 2 (7) | >0.05a |
| Baseline ALT level (IU/liter) | ||||
| Mean ± SD | 98 ± 120 | 119 ± 123 | 74 ± 113 | <0.001 |
| Median (range) | 56 (9–706) | 77 (19–706) | 40 (9–681) | |
| No. (%) with baseline ALT level above ULN | 119 (60) | 82 (78) | 37 (40) | <0.001 |
| No. (%) with HBeAg status of: | ||||
| Negative | 132 (67) | 65 (62) | 67 (73) | 0.10 |
| Positive | 65 (33) | 40 (38) | 25 (27) | |
| Baseline HBV DNA level (log10 IU/ml) | ||||
| Mean ± SD | 7.48 ± 8.02 | 7.66 ± 8.14 | 7.11 ± 7.49 | <0.001 |
| Median (range) | 6.46 (1.73–9.13) | 7.12 (2.09–9.13) | 5.42 (1.73–8.14) | |
| No. (%) with genotypic resistance | 74 (38) | 74 (80) | ||
| Median liver histology (range) | ||||
| Ishak stage | 2 (2–6) | 2 (2–6) | 2 (2–6) | 0.19 |
| HAI | 6 (5–15) | 7 (5–14) | 6 (6–15) | 0.11 |
| No. (%) treated with: | ||||
| TDF monotherapy | 126 (64) | 105 (100) | 21 (23) | <0.001 |
| Lamivudine-TDF combination | 71 (36) | 0 (0) | 71 (77) | |
| Treatment duration (mo) | ||||
| Mean ± SD | 28 ± 14 | 28 ± 14 | 29 ± 14 | 0.48 |
| Median (range) | 29 (6–52) | 28 (6–52) | 30 (6–51) |
a
Comparison of column proportions, χ2 test with Bonferroni adjustment.